PubMed Health⌕ Search

Biomedical subjects

G Rock

Publications and source records attributed to G Rock.

At least 19 recordsLinked to original sources

ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma.

BACKGROUND: ADAMTS-13 is implicated in the pathophysiology of thrombotic thrombocytopenic purpura (TTP). Plasma exchange is thought to be effective through removal of a harmful substance or provision of a required material such as ADAMTS-13. As various methods are used to prepare plasma we determined the effects of storage and solvent detergent treatment on the ADAMTS-13 levels in plasma. METHODS: Samples from fresh plasma and fresh frozen plasma (FFP) were stored at 22 degrees C and ADAMTS-13 levels were measured at 0, 12, 24, 48 and 72 h. Samples were also taken from solvent detergent treated plasma (SDP) and cryosupernatant plasma (CSP). Total protein, albumin, fibrinogen and immunoglobulins were also measured. RESULTS: In fresh plasma, the levels of both the 175 and 140 Kd subunits of von Willebrand factor were consistent at 1.38 and 1.35 OD units from 0 to 48 h indicating normal ADAMTS-13 activity. The Vitex SDP produced slightly more of the 140 Kd subunit than did Octapharma SDP which gave equivalent fragments. Cryosupernatant plasma was the same as normal plasma. None of these values changed over 48 h. There was a 28% decrease in FVIII in fresh plasma over 24 h. Fibrinogen and albumin were unchanged. CONCLUSION: ADAMTS-13 levels are not significantly decreased by storage of plasma at room temperature for up to 48 h. Both CSP and SDP also contained essentially normal levels of ADAMTS-13 and therefore could be used for treatment of patients with TTP.

ADAM Proteins↗

New methods showing in vitro changes of platelets.

INTRODUCTION: In vitro methods for assessing stored platelets are time consuming and variably correlate with in vivo survival. We used the ADVIA 120 and the Thromboelastogram (TEG) to assess changes during storage to determine a correlation of the results with those of other commonly used measures. METHODS: Platelet concentrates were tested at 1 and 5 days of storage. In vitro test included platelet count, aggregation response, the hypotonic shock response (HSR), The Kunicki morphology score (KMS) and platelet activation using CD62. The ADVIA was used to measure the platelet density and the granule content. The TEG measured the kinetics of clot formation. RESULTS: The platelet count and HRS did not change during storage. Aggregation decreased 50% by day 5. The KMS dropped from 307 at day 2-170. The MPC fell below 200g/l. There was slight platelet activation; the rate of clot formation decreased. CONCLUSIONS: Standard measures of in vitro platelet function indicated alterations during storage. A MPC of less than 200 corresponded to a Kunicki morphology score of less than 200. The TEG results correlated will with the KMS. These measurements may prove useful in predicting platelet survival and recovery.

Blood Platelets↗

Cryoprecipitate production: the use of additives to enhance the yield.

Cryoprecipitate is still widely used to treat hemophilia A in developing countries. However, the yield of factor VIII is relatively low averaging, i.e. only 50%. We have attempted to enhance the yield by adding sodium citrate to the plasma following the method of Shanbrom and Owens (Blood 98, 2001, 60a). Fresh-frozen plasma (FFP) units were processed either as control plasma or after the addition of 10% sodium citrate. Cryoprecipitate was produced from both. After resuspension, calcium chloride was added to the citrated cryoprecipitate to correct for excess citrate prior to testing. The levels of FVIII and fibrinogen were determined in both preparations. The citrated cryoprecipitates had varying yields of fibrinogen and FVIII in the cryoprecipitate. The FVIII levels varied from 34% to 215% recovery. Fibrinogen ranged from 55.5% to 121.4%. We found that the addition of increasing amounts of CaCl2 to normal plasma raised the FVIII values from 1.0 to 4 U/ml. To determine the possibility of assay influence we added different quantities of CaCl2 to control plasma and measured the FVIII and activated partial thromboplastin time levels. Addition of citrate to plasma resulted in an increased total amount of cryoprecipitate much of which was citrate. Assays showed considerable ranges in the quantity of FVIII and fibrinogen. Activation of FVIII can be caused by addition of excess calcium.

Calcium Chloride↗

A review of nearly two decades in an autologous blood programme: The rise and fall of activity.

Autologous blood donation (ABD) has been widely recommended. Data from one of the oldest hospital-based programmes in Canada describe both activities and drawbacks. Data were compared over the nearly two decades of activity that peaked in 1996. A 5-year review of recent activity showed that of the 2410 patients referred for consideration, 1823 (75.64%) were accepted into the programme. Surgical services requested 5825 units of autologous blood. Of these, 3147 units were donated by 1536 patients, 803 units were transfused in the operating room and 558 units were given postoperatively. In total, only 1361 units (43.25%) were transfused. The mean age of the patients was 58 years (median 61 years and mode 69 years). The haemoglobin concentrations before donation were significantly higher, averaging 145.2 g L(-1) before donation and 114.9 g L(-1) immediately before surgery, whereas at the time of discharge, the haemoglobin concentration averaged 126.2 g L(-1) (P = 0.0001) in transfused patients. Data from this well-established ABD programme indicate less than 50% overall utilization. The activity in the programme increased until 1996 following which it dropped progressively. The low haemoglobin concentration after surgery is of concern and should foster a transfusion algorithm for these patients.

Blood Donors↗

The contribution of platelets in the production of cryoprecipitates for use in a fibrin glue.

BACKGROUND AND OBJECTIVES: Cryoprecipitate has a wide application for use as a fibrin glue. In some situations, platelets are added to the preparation in order to enhance the fibrin glue. MATERIALS AND METHODS: Fresh plasma was collected by apheresis from the same donor to produce 250 ml of platelet-rich plasma (PRP) or platelet-poor plasma (PPP) (n = 12 each). Cryoprecipitate was then produced following the standards of the American Association of Blood Banks and resuspended to a total volume of 8 ml, from which aliquots were removed and assayed. Clot formation was measured using the thromboelastogram. RESULTS: The protein content of the two preparations was identical for PRP and PPP. Results for fibrinogen (PPP 475 +/- 220 mg; PRP 399 +/- 215 mg), Factor VIII (PPP 186 +/- 67 IU; PRP 175 +/- 70 IU) and von Willebrand Factor (PPP 260 +/- 104 IU; PRP 221 +/- 88 IU) were not significantly different. The concentration of platelet-derived growth factor was markedly higher (a 100-fold increase at 3778 +/- 1036 ng) when platelets were added to the plasma. There was a small, but not statistically significant, difference in the rate of clot formation (R = 2.3 for PPP and 3.8 for PRP) and clot strength (MA = 63.4 for PPP and 56.6 for PRP) between PPP and PRP cryoprecipitates when measured using the thromboelastogram. CONCLUSIONS: Platelets do not significantly increase the concentration of the usual constituents of cryoprecipitate; however, the levels of platelet-derived growth factor are markedly enhanced. Therefore, there are advantages for using PRP to enhance the growth of new tissue.

Blood Platelets↗

Current perceptions of Canadian autologous blood donors.

BACKGROUND AND OBJECTIVES: We determined the perceptions and motivations of autologous donors to establish their regard for this process and the new blood system established in 1999 in Canada. MATERIALS AND METHODS: Patients were surveyed before and after orthopaedic, cardiac, urological or gynecological procedures. RESULTS: Patients (n = 100; 57 men and 43 women) ranged in age from 19 to 83 years. Most had finished high school, and 21 had a university degree. Eighty-four had undergone previous surgery and 27 a previous transfusion. Fifty-one had been blood donors and 17 had been autologous donors. Specialists suggested donation to 78 of the patients. Seventy-two participated because they knew that their blood would be there. Three had a mistrust of the blood provider. Sixty-six believed that there is still a risk of receiving contaminated blood. Sixty-nine thought any risk was > or = 1 in 100,000; however, 16 thought the risk was < 1 in 1000. Postsurgery, 83 were happy to have donated their blood and 77 would do it again. Many felt that it improved their outcome. Most felt an increased sense of safety. Eighty-three patients were confident that the Canadian blood system had improved, but 17 were unsure. CONCLUSIONS: Concern about the safety of the allogeneic blood supply still drives the wish to autodonate. The process gives patients a sense of control and security. A large proportion of people felt that the Canadian blood system had improved, as determined by this 2003 study.

Adult↗

The development of an optimized autologous blood donation program.

BACKGROUND: Autologous blood (ABD) programs have been in place in Canada since the late 1980s. Activity is decreasing in many sites and utilization averages 50%. METHODS: In an effort to optimize our ABD program we introduced one time single donation red cell collection (Trima) with and without erythropoietin and compared the results to those with standard red cell collections. A pre-pilot study assessed feasibility. RESULTS: To date a total of 59 patients have entered the three arm Trima/epo pilot involving prostate surgery patients: their pre-surgical Hg 158 was compared to 108 in normal autologous control patients. By decreasing the standard pre-donation autologous requirement of three units of red cells to a single Trima collection and at $300 per autologous unit, this represents a cost savings of $36,000 in our 59 patients. When applied to the total autologous program at our hospital (450 per year), this extrapolates to a minimum savings of over $250,000 when using combined collection approaches. 32/59 patients in this pilot study have received only autologous blood, again reducing the number of allogeneic units that would have been required. The need for only a single autologous donation cuts nursing time by 2/3 and also saves laboratory money, since only a single unit is tested for infectious diseases. CONCLUSION: When applied to an autologous blood program, the use of the Trima machine combined with erythropoietin in appropriate cases, results in a decrease in the number of units collected and a higher pre-operative hemoglobin. This program should see application in other sites.

Blood Donors↗

Development of a total quality system for transfusion medicine services in Ontario hospitals.

TOTAL QUALITY SYSTEM: The purpose of the project was to develop a total quality system in Transfusion Medicine which would serve as a model for development of a provincial transfusion quality system. Pilot studies were carried out in Ottawa and Hamilton/Niagara. Each region was provided with resources to create a Quality Team. The Quality Team was comprised of several individuals including a Quality Team Leader, and a number of Quality Assistants. The responsibilities of the Quality Team included: working with Transfusion Medicine Laboratories in area hospitals to achieve a total quality system, identification, standardization and implementation of 'best transfusion practices' throughout the regional hospitals, development and implementation of standard operating procedures (SOP) based on best practices, development and implementation of transfusion/administration guidelines, assessment of blood utilization, education, training, non-conformance (error) management, and surveillance. Liaison was also established with the co-coordinator for the Transfusion Co-coordinator's Project (ONTRAC), the education coordinator for the Sunnybrook Project, the Public Health Agency of Canada, Quality Management Practice-Laboratory System, the Ontario Hospital Association and Laboratory Licensing. In Ottawa these activities resulted in the development of:

Blood Banks↗

World apheresis association--world apheresis registry.

In 2002 WAA decided to start a world-wide apheresis registry to gain insight into the extent of treatment, adverse events, and to facilitate contacts among centers when treatment indications are rare and experience limited. Stem cell and other blood products collections intended for therapeutic application can also be entered. The WAA planned to use the French Registry. Its translation into English has not been accomplished and the fiscal obligations for that registry has not, as yet, been determined or considered and approved by the WAA Board. From Dec 2002 the proposed registry (a merged version of the French, Canadian and Swedish registries) can be immediately implemented. We now cordially invite all centers to join that registry. Please, also inform colleagues at other centers in your country to join. E-mail and address lists of colleagues in your country who have not registered will be welcomed. The site is at: Go to World Apheresis Registry; Login code to test the Registry is: al61tms. Then apply for a specific login code for your center. We welcome you to this registry for your input of data. You will not be charged any registration fee. The registry includes a randomization system that can be used for local or multi center studies (randomization by in-center basis allows you to make your own studies). It includes a formula that increases the chance to get a more even distribution between groups also for smaller sample sizes.

Blood Component Transfusion↗

The use of a bacteria detection system to evaluate bacterial contamination in PLT concentrates.

BACKGROUND: Random-donor PLTs (RDPs) are functional at 7 days. Nevertheless, since the mid-1980s, concern for bacterial contamination has caused the storage period to be reduced to 5 days. The ability of a bacteria detection system (BDS, Pall) to determine bacterial contamination and permit extension of the PLT shelf life to 7 days was assessed. STUDY DESIGN AND METHODS: Blood was collected into CP2D and leukoreduced RDPs were prepared. Upon arrival at the hospital, a 2- to 3-mL aliquot was removed from each RDP and introduced into the Pall BDS pouch with a sterile docking device. The pouch was incubated at 37 degrees C for 24 hours and then the oxygen content was measured to determine bacterial contamination. Additionally, the RDPs were pooled and an aliquot was removed for culture with standard manual techniques. CCIs were calculated 1 hour after infusion. RESULTS: A total of 12,062 individual RDPs were tested. The Pall BDS detected bacteria in 5 units. All of these were positive on repeat sampling. Propionibacterium acnes, coagulase-negative Staphylococcus, and Bacillus species were confirmed by manual technique in 3 units, one could not be identified, and one was negative. Aliquots from PLT pools were positive in 80 of 2201 pools when tested by manual methods. Of these, 79 were false-positives and 1 unit contained coagulase-negative Staphylococcus. The Pall BDS was easy to use and required less than 5 minutes for all manipulations. After 7 days of storage, the PLTs gave an average CCI of 16 x 10(11)+/- 3.39 x 10(11) 1 hour after transfusion (n = 9). CONCLUSIONS: The Pall BDS permits evaluation of RDPs for bacterial contamination. Culture-negative PLTs were successfully transfused in our institution up to and including 7 days after storage with good CCIs.

Bacillus↗

The Canadian apheresis registry.

Apheresis is a procedure in which a specific blood component is selectively removed from a patient using computerized machines. In Canada it is currently used to treat over 30 different diseases, and, in 2002 a total of 8600 plasma exchange procedures were performed at a cost of over 7 million Canadian dollars. The Canadian Apheresis Group (CAG) is a national, volunteer organization of physicians and nurses who have special interest in evaluating the appropriate application of therapeutic apheresis (TA). It was formed in 1980 under the auspices of the Department of National Health and Welfare with the goals of providing a forum for the exchange of information among apheresis practitioners in Canada and developing statistically sound, prospective clinical trials to test the efficacy of plasma exchange as treatment for various disorders. The group includes representatives from each of the major medical centres in Canada so that there is a liaison between the CAG and local medical communities across the country. Over the years the group has been funded by Health Canada, then the Canadian Blood Committee, the Canadian Blood Agency and, for the past 3 years, by the Canadian Blood Services and the Province of Quebec. The CAG was the first group to organize a national database and, since 1981, has collected data from 42 apheresis units throughout Canada and more than 140,000 plasma exchange procedures. In 1981 there were 4716 plasma exchanges done while in 2002 there were 8561. This total has been relatively stable at approximately 8500 for each of the last 4 years. However, 20 years ago exchanges for hematological and neurological disorders each constituted 30% of the total and 15 years ago the majority of procedures were performed for neurological disorders (50%). In 2002 the majority of procedures were performed for hematological disorders (55%) and neurological disorders had fallen to 40% of the total. We believe these changes have been of a controlled and appropriate nature as a result of the activities of the CAG. We have developed national practice guidelines and have directed studies in a number of diseases, the results of which have refined practice across the country. We have also monitored replacement fluids and have had a significant effect on the appropriate use of plasma or albumin. Over the past 22 years, the activities of the CAG have lead to a rational, cost effective, use of TA in our country, have promoted the dissemination of knowledge among apheresis practitioners and have fostered optimal patient care.

Blood Component Removal↗

Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution.

Immunoadsorption is occasionally used as an adjuvant measure in the treatment of subjects with coagulation factor inhibitors. We reviewed our recent 3-year period experience with this procedure in 10 subjects. Immunoadsorption was used in the context of an immune tolerance protocol for 3 subjects with severe congenital deficiency in factor VIII, IX, and XIII; it was effective in lowering the level of inhibitor but immune tolerance was not achieved. It allowed successful use of porcine factor VIII in 4 cases of acquired hemophilia and in one case of inhibitor in mild hemophilia A. This therapeutic approach seems to be more useful in acquired hemophilia than in severe congenital factor deficiencies with inhibitors.

Adult↗

Automated collection of blood components: their storage and transfusion.

The performance of an automated device, the Gambro TRIMA, was evaluated for component production, and an in vivo assessment of the platelets was carried out. Red cell concentrates (RCCs), platelets and plasma were collected and stored according to standard blood bank procedures and evaluated for quality by in vitro measurements. Additionally, single-donor platelets (n=10) were transfused to thrombocytopenic patients after 5 days of storage. Platelet counts were measured after 1 h and the corrected count increment (CCI) was calculated. No significant changes were seen before or after procedure in donor haemoglobin, haematocrit, coagulation factors or platelet count. Return-line samples showed no increase in the level of plasma haemoglobin. Plasma haemoglobin and potassium increased following RBC storage, but there was no change in the red cell number. Platelet aggregation decreased from 52 to 11% (adenosine diphosphate) and the Kunicki morphology score dropped from 379 to 174. Little change was seen in the hypotonic shock response (69-63%) or in the percentage of CD62 expression (4.8-19.8) over time. The CCI averaged 28+/-26 x 10(3) microL(-1) in 10 patients 1 h after transfusion. The TRIMA machine collects RCCs, platelets and plasma in a variety of combinations in one session. For autologous collection, two units of RCC plus platelets can be collected at one time, reducing administrative and testing costs. The platelets have good in vivo recovery, as shown by the CCI values. An added advantage is that the TRIMA machine can be used in hospitals to generate components in times of shortage without the need for a component's laboratory.

Automation↗

A pilot study to assess physician knowledge in transfusion medicine.

INTRODUCTION: An assessment of transfusion medicine knowledge and practice in Canada was carried out over a 3-week period. METHODS: Fifty-five questions were posed to evaluate both basic information on blood and blood products and on clinical use. The form was distributed through the Canadian Society for Transfusion Medicine with designated individuals asked to handle regional distribution. Some used provincial mailing lists, others distributed within each hospital. Approximately, 2000 forms were sent, including 500 in French. RESULTS: A total of 294 forms were returned; answers were recorded as 'correct', 'incorrect', 'no answer' or with 'added comments'. Overall, 52% of the questions were answered correctly or were answered with qualifying comments. In clinical practice questions, 63% were answered correctly or with qualifying comments. Basic knowledge questions drew correct answers in 37% of the cases. Several issues were answered poorly. The volume of an apheresis plasma unit was correctly estimated by less than 10% of respondents with many understanding the volume (500-600 mL) by as much as 300-400 mL. Anaesthesiologists responded most often (21%); few haematologists participated (4%). Provincial response varied: most were received from Ontario (30%) and British Columbia (22%). CONCLUSIONS: The answers show that clinical application of transfusion is generally accompanied by a questioning process - it is not entirely by rote. Basic knowledge about products needs improvement.

Blood Transfusion↗

Perceptions and motivations of Canadian autologous blood donors.

Preoperative autologous blood donation in Canada has increased in the last decade due to concerns about allogeneic blood safety. As economic policies necessitate the validation of autologous blood donation, it is important to assess potential changes. This study examines the motivations and perceptions of patients participating in a Canadian autologous blood donation programme. The study was conducted at the Ottawa Hospital, Civic Campus. Questionnaires were developed and then administered to 100 consecutive adult autologous blood donors. The questionnaires assessed patient demographics, motivation for participation and perceptions about blood safety. Autologous donation was presented to 82% of patients as an option by their physicians. However, 59% of all patients felt that they were motivated to donate by their own fears. Patients (87%) also felt that directed blood donation should be offered due to their perception that directed donation is safer. Three-quarters of patients would be willing to pay for autologous donation. Patients are concerned about the safety of allogeneic blood and they are motivated to seek other alternatives despite the fact that allogeneic blood is very safe. These perceptions and motivations must be taken into account as health care policy changes are considered.

Adolescent↗

Age of blood in inventory at a large tertiary care hospital.

BACKGROUND AND OBJECTIVES: This major tertiary care centre transfers over 1000 red cell units monthly. Units are rotated as part of inventory management to ensure minimum wastage. In 1998, the expiration date of AS3 red cells was extended from 35 to 42 days, potentially affecting inventory. MATERIALS AND METHODS: The average age of the red cell units in inventory on any given day was evaluated to determine whether the extended expiration date would affect blood availability and to determine the feasibility of using blood at different ages for various purposes. Over a 6-month duration, 20 days were selected for review: units were categorized according to ABO group and Rh type and then analysed for age within certain categories. RESULTS: The average age of the blood in inventory was 1 to 2 weeks. The probability of having units less than 1-week old was highest for Group O and zero for Group B Rh(+) and Group AB Rh(+). More than 60% of the O Rh(-) blood was older than 28 days. CONCLUSION: The age of units in inventory varies with respect to ABO group, Rh type and weekday. In practice, the stock rarely reaches 42 days of age. Future studies on the effects of age of blood on patient outcome must consider the logistics of supply and the availability of blood of each group. Transfusion of large numbers of units of the same age and of a specific blood group and type may not always be possible.

ABO Blood-Group System↗